achondroplasia

News

Ascendis scores FDA approval for weekly dwarfism drug

Children with achondroplasia will soon have the option of a once-weekly - rather than daily - injection, courtesy of Ascendis' newly approved Yuviwel.

News

BridgeBio gains on phase 3 dwarfism data

Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.

News

Pfizer acquires Therachon and its dwarfism drug

Pfizer has announced it will pay $340 million upfront to snap up rare disease biotech Therachon, which is developing treatments for a form

Ascendis scores FDA approval for weekly dwarfism drug

BridgeBio gains on phase 3 dwarfism data

Pfizer acquires Therachon and its dwarfism drug

argenx's Forte acquisition delivers coeliac trial win

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks